Advice
Following a full submission.
Pegaptanib for intravitreal injection (Macugen) is accepted for restricted use within NHS Scotland for the treatment of neovascular (wet) age-related macular degeneration (AMD).
It has been shown to reduce the rate of loss of visual acuity in patients with subfoveal neovascular AMD. Pegaptanib should be restricted to patients with visual acuity between 6/12 to 6/60 (inclusive) and should be stopped if visual acuity falls below 6/60 during treatment or where severe visual loss is experienced.
The cost effectiveness of pegaptanib in patients who are also receiving photodynamic therapy has, however, not been demonstrated.
Download detailed advice47KB (PDF)
Medicine details
- Medicine name:
- Pegaptanib (Macugen)
- SMC ID:
- 290/06
- Indication:
- Neovascular (wet) age-related macular degeneration
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Eye
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 07 August 2006